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Abstract
Background: We previously identified Mycobacterium tuberculosis (M.tb) antigen-induced host markers that showed
promise as TB diagnostic candidates in 7-day whole blood culture supernatants. The aim of the present study was to
evaluate the utility of these markers further, and cross-compare results with short-term antigen stimulated and
unstimulated culture supernatants.
Methods: We recruited 15 culture confirmed TB cases and 15 non-TB cases from a high-TB endemic community in Cape
Town, South Africa into a pilot case-control study from an on-going larger study. Blood samples collected from study
participants were stimulated with 4 M.tb antigens that were previously identified as promising (ESAT6/CFP10 (early
secreted), Rv2029c (latency), Rv2032 (latency) and Rv2389c (rpf)) in a 7-day or overnight culture assay. Supernatants were
also collected form the standard QuantiFERON In Tube (QFT-IT) test. The levels of 26 host markers were evaluated in the
three culture supernatants using the Luminex platform.
Results: The unstimulated levels of CRP, Serum amyloid P (SAP) and serum amyloid A (SAA) and ESAT-6/CFP-10 specific IP-
10 and SAA were amongst the best discriminatory markers in all 3 assays, ascertaining TB with AUC of 72–84%. Four-marker
models accurately classified up to 92%, 100% and 100% of study participants in the overnight, 7-day and Quantiferon
culture supernatants, respectively, after leave-one-out cross validation.
Conclusion: Unstimulated and antigen-specific levels of CRP, SAA, IP-10, MMP-2 and sCD40L hold promise as diagnostic
candidates for TB disease in short-term stimulation assays. Larger studies are required to validate these findings but the data
suggest that antigen-specific cytokine production and in particular mutimarker biosignatures might contribute to future
diagnostic strategies.
Citation: Essone PN, Chegou NN, Loxton AG, Stanley K, Kriel M, et al. (2014) Host Cytokine Responses Induced after Overnight Stimulation with Novel M.
tuberculosis Infection Phase-Dependent Antigens Show Promise as Diagnostic Candidates for TB Disease. PLoS ONE 9(7): e102584. doi:10.1371/journal.pone.
0102584
Editor: Francesco Dieli, University of Palermo, Italy
Received February 13, 2014; Accepted June 20, 2014; Published July 15, 2014
Copyright:  2014 Essone et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors acknowledge the EDCTP (grant IP. 09.32040.011), EC FP7 NEWTBVAC contract no. HEALTH.F3.2009 241745, EC FP7 EURIPRED contract no.
INFRASTRUCTURES.2012.1 312661 and EC FP7 VACTRAIN (the text represents the authors’ views and does not necessarily represent a position of the Commission
who will not be liable for the use made of such information). Paulin Essone is funded by ‘‘Agence nationale des bourses du Gabon’’. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The author THMO is co-inventor on the following patent: EP05075748.3 entitled: ‘‘Methods and means for diagnostics, prevention and
treatment of Mycobacterium infections and tuberculosis disease’’. Exclusive rights have been given to ISA Pharmaceuticals B.V., Bilthoven, The Netherlands.
Authors NNC and GW hold three patent rights on cytokine---based diagnostic signatures for TB disease with PNE a co-inventor on one of the provisional patents:
1.) South African Provisional Patent application no: 2014/02743. Title: A METHOD FOR DIAGNOSING TUBERCULOUS MENINGITIS. Date: 15 April 2014. Inventors:
CHEGOU Novel Njweipi, WALZL Gerhard, VAN FURTH Anne Marceline, VISSER Douwe Hendrik. 2.) South African Provisional Patent Application No: 2014/01456.
Title: SERUM HOST MARKERS FOR TB. Date: 26 February 2014. Inventors: Chegou Novel Njweipi, Gerhard Walzl, Mihret Adane. 3.) International Patent Application
No. PCT/IB2013/054377. Title: Method for the diagnosis of TB disease. Date filed: 27 May 2013. Inventors: Gerhard Walzl, Chegou Novel Njweipi Ndong Paulin
Essone. None of the authors receives any financial or other remuneration from the patenting rights. The patenting rights did not influence authors’ interpretation
of the data presented in this manuscript and furthermore, do not alter the authors’ adherence to all PLOS ONE policies on sharing data and materials, as detailed
in the online guide for authors. No other competing interests exist.
* Email: gwalzl@sun.ac.za
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e102584
Background
The diagnosis of tuberculosis (TB) disease remains a challenge
in resource-constrained settings [1]. The sputum based tests widely
used to diagnose active TB have many limitations: staining for acid
fast bacilli, the most widely used test has poor sensitivity [2,3].
Sputum culture remains the gold standard method for TB
diagnosis but fails to deliver results in a time effective manner
[4]. The automated real-time sputum processing molecular
beacon assay, XpertMTB/RIF assay (Cepheid Inc., CA, USA)
yields results within 2 hours, with high sensitivity and specificity
(98–100%) in smear positive but moderate sensitivity (68–72%) in
smear negative TB cases [5,6]. Cost effectiveness of the
GeneXpert test remains one of the major impediments to the
large-scale roll-out of the test in high burden but resource-
constrained settings [7,5]. Alternative methods such as serological,
urine based [8,9], and other immunological tests have been
investigated but these tests do not yield consistent results. The use
of the available commercial serological tests was subsequently
discouraged by the WHO [1].
Interferon gamma (IFN-c) release assays (IGRAs) have added a
new dimension to the immune-based diagnosis of TB, as these tests
are highly specific and accurate in the diagnosis of Mycobacterium
tuberculosis (M.tb) infection, especially when compared to the skin
test [10]. However, IGRAs do not differentiate between active TB
disease and latent infection and although useful in low incidence
settings, they are only used for research purposes in high burden
areas [1,10,11]. Alternative M.tb specific antigens [12–13], and
alternative host markers other than IFN-c in M.tb-specific antigen-
stimulated whole blood culture assays have been investigated for
TB diagnostic purposes [14], [15]. In one of these studies [15] we
showed that the measurement of many host markers (including
interferon-inducible protein (IP)-10, tumour necrosis factor (TNF)-
a, IFN-c, interleukin (IL)-12p40, transforming growth factor
(TGF)-a, vascular endothelial growth factor (VEGF) and
RANTES (CCL5)) upon stimulation with novel M.tb infection
phase-dependent antigens (including Rv0081, Rv2032, Rv1737c,
Rv2389c and Rv0867c) in culture supernatants showed potential
in the diagnosis of TB disease [15]. However, in those studies we
employed a long term (7-day) whole blood culture method, which
might not be very suitable for diagnostic purposes. In the current
study, we investigated whether these novel antigens [15] can also
induce host markers after stimulation in short-term (overnight)
assays and whether the diagnostic potential observed after 7-day
WBA is maintained. We show that these antigens induce the same
and other host markers in overnight culture assays, and maintain
their diagnostic potential.
Materials and Methods
Study participants
The study was performed as a pilot study to a larger study, the
EDCTP-funded African-European Tuberculosis Consortium (AE-
TBC) project, that was conducted in 7 African and 5 European
institutions (www.ae-tbc.eu). Participants visiting a clinic in one of
the African sites, the Ravensmead/Uitsig community clinic in the
Western Cape Province of South Africa, with symptoms suspicious
of TB and on whom the clinician was willing to consider for
further TB tests were enrolled into the study. All study participants
underwent a thorough clinical workup including chest x-rays and
HIV testing using a rapid test (Abott, Germany). Blood and
sputum samples, along with other samples needed for routine
clinical investigations were collected from all study participants.
Sputum samples were cultured using the MGIT method (BD
Biosciences). Isolation of M.tb complex organisms was confirmed
in all positive cultures by means of an M.tb complex specific PCR
[3]. Participants were eligible for the study if they were $18 years
old, had no previous history of TB, were not pregnant, were not
involved in a drug or vaccine trial and if they had no other known
chronic diseases like diabetes mellitus. According to the TB test
outcomes, participants were divided into two groups; confirmed
TB cases (the TB disease group in this manuscript) and alternative
pulmonary disease (referred to as the ‘‘Non-TB’’ cases in this
study). None of the participants in the non-TB group was treated
for TB by the national TB control program during the 6 month
follow up period of the study. All participants provided written
informed consent for participation in the study including for HIV
testing, storage and use of the samples for immunological
biomarker discovery purposes. Ethical approval for the study
was obtained from the Human Research Ethics Committee of the
University of Stellenbosch (N10/08/274).
Whole blood culture assays (WBA)
About 10 ml of whole blood was collected from all study
participants into heparinized tubes for overnight and long term (7-
day) WBAs. Furthermore, 3 ml of blood was collected directly into
QFT-IT tubes (Qiagen, Germany).
Four recombinant proteins, generated at Leiden University
Medical Centre, The Netherlands, (Rv2029c, Rv2032, Rv2389c
and ESAT6/CFP10 fusion protein), previously described in [12,
[15] [16], were available for evaluation in this study. All the
antigens were reconstituted and evaluated at a final concentration
of 10 mg/ml in an overnight and 7-day WBA as follows:
The 7-day WBA was performed as previously described [12].
Briefly, lyophilized antigens were reconstituted in sterile 1x PBS and
diluted to a concentration of 20 mg/ml with RPMI 1640 containing
L-glutamine (Sigma Aldrich, Steinheim, Germany). The diluted
antigens (100 ml at 20 mg/ml) as well as the medium (unstimulated
Table 1. Clinical and demographic characteristics of study participants.
All Pulmonary TB No TB
Number of participants(n) 30 15 15
Mean age, years (SD) 29.9(6 12.5) 26(6 14.2) 33.5(6 10.2)
Male/female ratio 6/24 4/11 2/13
HIV status, (positive/negative) 3/30 0/15 3/15
Participants with QFT-IT test results 27 13 14
QFT-IT positive, n (%) 19(70.4) 12(92.3) 7(50)
doi:10.1371/journal.pone.0102584.t001
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control), were then seeded into 96-well plates in triplicates after
which plates were frozen at 280uC until the day of WBA. On the
day of WBA, pre-frozen antigen plates were allowed to thaw after
which whole blood was diluted 1 in 5 in pre-warmed (37uC)
RPMI1640 medium containing glutamine, and then 100 ml of the
diluted blood added into each well containing the antigens or
control. The plate was then incubated at 37uC at 5% CO2 until day
7 after which supernatants were harvested, aliquoted and stored at
280uC until testing using the Luminex platform (described below).
For the overnight WBA, the reconstituted antigens (in sterile 1x
PBS) were diluted to a concentration of 100 mg/ml using sterile 1x
PBS. Each diluted antigen (at 100 mg/ml) was then aliquoted in
100 ml amounts and frozen at 280uC in micro centrifuge tubes
(Eppendorf Germany). On the day of WBA, an aliquot of each
antigen (100 ml at 100 mg/ml) was thawed and added to 1 ml of
undiluted whole blood in 24-well tissue culture plates (Corning
Costar, Sigma). 100 ml of sterile 1xPBS was added to a single well of
the 24-well plate for each participant and evaluated as the
unstimulated control. After mixing, plates were incubated for 20
to 24 hours at 37uC in a 5% CO2 atmosphere. Supernatants were
harvested, aliquoted and frozen at280uC until evaluated using the
Luminex platform.
The QFT-IT assay was performed according to the manufac-
turer’s instructions as previously described [14]. Briefly, after
overnight incubation of the blood in the QFT-IT tubes, superna-
tants were harvested, aliquoted and frozen at 280uC. Aliquots of
supernatants from all participants were used for IFN-c ELISA using
kits supplied by the manufacturer, and interpreted for M.tb infection
using the manufacturer’s recommended criteria (Qiagen, Ger-
many). Other aliquots were used for the Luminex assay.
Luminex multiplex immunoassay
A total of 26 host markers, namely epithermal growth factor
(EGF), fractalkine, IP-10, monocyte chemotactic protein (MCP)-1,
macrophage inflammatory protein (MIP)-1a, MIP-1b, soluble
CD40 ligand (sCD40L), TGF-a, TNF-a, VEGF, matrix metallo-
proteinase (MMP)-2, MMP-9, RANTES, C-reactive protein
(CRP), serum amyloid A (SAA), serum amyloid P (SAP),
Interferon (IFN)-a2, IFN-c, IL-1a, IL-12p40, IL-15, IL-17, IL-4,
IL-10, IL-1b and IL-12p70, were evaluated in overnight, 7-day,
and QFT-IT culture supernatants from the same study partici-
pants, using customized Milliplex kits (Merck Millipore, St.
Charles, Missouri, USA). Assays were performed on the Bio-Plex
platform (Bio-Rad Laboratories, Hercules, USA) according to the
instructions of the kit manufacturer (Merck Millipore). Prior to
assaying, samples for the detection of CRP, SAA and SAP were
diluted 1 in 8000 using the assay buffer provided in the kit,
following optimization experiments. To enable the accurate
detection of all the other host markers evaluated, the overnight
WBA and QFT-IT culture supernatants were diluted 1in 2 using
the kit serum matrix as previously described [12], whereas the 7-
day WBA supernatants were tested neat (undiluted) [15]. Samples
were evaluated in a blinded manner. All analyte levels in the
quality control reagents provided by the kit manufacturer were
within the expected ranges. The values obtained for all host
markers were automatically corrected for the dilution by the
software used for bead acquisition and analysis of median
fluorescence intensity (Bio-Plex Manager Software, version 4.1.1).
Statistical analysis
Comparison between groups (for example TB vs. no TB) was
done using the Mann Whitney U test for non-parametric data
analysis. The accuracy of all antigen-induced host markers for the
diagnosis of TB disease was estimated by performing receiver
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operator characteristics (ROC) curve analysis. Optimal cut-off
values were selected based on the Youden’s index, defined as the
largest difference between the sensitivity and 1-specificity, taken
over all points on the ROC curve [17]. The predictive abilities of
combinations of analytes for TB disease were investigated by
performing best subsets general discriminant analysis (GDA), with
leave-one-out cross validation as previously described [12]. Data
were analysed using the Statistica software (Statsoft, Ohio, USA)
and GraphPad prism, version 5.0 (GraphPad Software, San
Diego, CA, USA).
Results
Study participants
Of the 30 participants enrolled into this study, 6 (25%) were
males. The mean age of all study participants was 30.0612.7
years. All the 15 study participants with TB disease had sputum
culture and M.tb-PCR-confirmed pulmonary TB. Of all the 27
participants in whom QFT-IT testing was done (13 TB cases and
14 non-TB cases), 19 (70.4%) were positive (12 TB cases and 7
non-TB cases) using the manufacturer’s recommended cut-off
value ($0.35IU/ml). The clinical and demographic characteristics
of all study participants are shown in table 1.
Utility of host markers detected in 7-day antigen-
stimulated culture supernatants in the diagnosis of TB
disease
The unstimulated or antigen-specific levels of 8 of the 26 host
markers evaluated (fractalkine, IFN-a2, SAA, IP-10, EGF, IFN-c,
MMP-2, MMP-9) were significantly different (p,0.05) between
the TB cases and controls (50% of whom were QFT-IT positive)
either in the 7-day unstimulated supernatants, or following 7-day
stimulation with at least one of the four antigens evaluated.
The unstimulated levels of fractalkine and SAA were signifi-
cantly higher in TB cases whereas the unstimulated levels of IFN-
a2 and MMP-2 were higher in the non TB cases (table 2).
When the antigen-specific responses were calculated by
subtraction of the unstimulated levels from those obtained after
stimulation with the respective antigens, ESAT-6/CFP-10-specific
levels of EGF, IP-10 and MMP-9 were significantly higher (p,
0.05) in TB cases (table 2, figure 1). Following stimulation with
Rv2029c, only MMP-9 responses were significantly different
between the TB and no TB cases (higher in the TB cases).
Similarly, Rv2389c elicited the production of higher levels of
MMP-9 and EGF in the TB cases. Only EGF levels were
significantly different between the TB and non TB cases (higher in
TB cases) following stimulation with Rv2032 (table 2).
When the diagnostic accuracy of the markers obtained in
supernatants after 7-day stimulation of whole blood with the
antigens was evaluated by ROC curve analysis, the area under the
ROC curve (AUC) was above 0.70 (an arbitrary AUC cut-off
value used in previous studies) [15] [12], for ESAT-6/CFP-10
specific levels of EGF, IP-10 and MMP-9, Rv2029c-specific levels
of MMP-9, Rv2389c-specific levels of EGF and MMP-9, Rv2032-
specific levels of EGF, as well as the unstimulated levels of
fractalkine, IFN-a2, MMP-2 and SAA (table 2). Using the cut-off
values derived after ROC analysis, the unstimulated levels of
fractalkine and Rv2389c-specific levels of MMP-9 ascertained TB
disease with sensitivities of 100% and 93% respectively, but with
lower specificities (53% and 79% respectively). ESAT-6/CFP-10
specific MMP-9 was the only marker that ascertained TB disease
with both sensitivity and specificity $80% (table 2).
When the accuracy of combinations of markers was assessed by
general discriminant analysis (GDA), optimal prediction of TB
disease was achieved if markers were used in combinations of four.
Seven different GDA prediction models accurately classified all the
study participants (100%) into their appropriate clinical groups.
After leave-one-out cross validation, these models could still
correctly classify 100% of the non-TB cases, but only #80% of the
individuals with active TB (table 3). The most accurate prediction
model (ESAT-6/CFP-10-specific EGF, Rv2032-specific VEGF,
Rv2029C-specific IL-1beta and Rv2389c-specific MMP-9) accu-
rately classified all participants (100%) after leave-one-out cross
validation (table 3). The most frequently occurring analytes in the
20 most accurate predictive models included ESAT-6/CFP-10
specific EGF, Rv2029c-specific SAP and Rv2029c-specific SAA
(figure 2).
Figure 1. Scatter-dot plots and ROC curves in 7-day WBA. Representative dot plots showing the levels of analytes in the 7-day whole blood
culture supernatants and ROC curves for accuracy in the diagnosis of TB disease. Error bars in the dot plots represent the median analyte levels.
Representative analytes with AUC$0.80 are shown.
doi:10.1371/journal.pone.0102584.g001
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Utility of host markers detected in overnight culture
supernatants (in-house assay) in the diagnosis of TB
disease
The unstimulated or antigen-specific levels 9 markers (MMP-2,
sCD40L, IP-10, IFN-c, TNF-a, SAA, SAP, and CRP) showed
significant differences between the TB cases and controls.
Unstimulated CRP and SAA levels were significantly higher in
the TB cases. ESAT-6/CFP-10-specific levels of IP-10, sCD40L,
TNF-a, IFN-c and SAP were significantly higher in TB cases.
Similarly, Rv2389c-specific levels of SAP and CRP, and Rv2032-
specific levels of SAP were higher in the TB cases whereas
Rv2032-specific MMP-2 was higher in the non TB cases (table 4,
figure 3). When the diagnostic accuracies of the markers detected
in overnight culture supernatants were assessed by ROC curve
analysis, all the markers that showed significant differences
between groups ascertained TB disease with AUC.0.70 (range,
0.71 to 0.83). ESAT-6/CFP-10-specific IP-10 and IFN-c, Rv2032-
specific MMP-2 all diagnosed TB disease with sensitivity $93%,
but specificity was low for some markers (e.g. 67% for ESAT-6/
CFP-10-specific IP-10). By contrast, unstimulated CRP levels
ascertained TB with low sensitivity (60%) but with very high
specificity (100%) (table 4).
When the data obtained from overnight culture supernatants
were analysed by the GDA procedure, optimal prediction of TB or
no TB disease was achieved if markers were used in combinations
of four. The most accurate 4-analyte model (Rv2029c-specific
TNF-a+Rv2032-specific IFN-a2+Rv2032-specific SAP+Rv2389c-
specific IL-15) accurately classified 92% of the TB cases and 85%
of non TB cases after leave-one-out cross validation (table 5). The
most frequently occurring analytes in the top 20 predictive models
included unstimulated TGF-a and Rv2029c-specific SAP (figure 2).
Utility of host markers detected in QFT-IT culture
supernatants in the diagnosis of TB disease
The unstimulated or antigen-specific levels of 11 markers
(MCP-1, MIP-1b, VEGF, IP-10, IL-10, IL-1b, TGF-a, CRP,
SAA, SAP and MMP-9) showed significant differences when
evaluated in QFT-IT supernatants, with most of the discrimina-
tory markers being detected in unstimulated supernatants. The
unstimulated levels of 7 markers (MCP-1, MIP-1b, VEGF, IL-10,
IL-1b, TGF-a, CRP and MMP-9) were significantly higher in the
non-TB cases while the unstimulated levels of CRP, SAA, SAP
and IP-10 were significantly higher in the TB cases. The antigen-
specific levels of MCP-1 and IP-10 were significantly higher in the
TB cases (table 6, figure 4). When the diagnostic accuracy of the
data obtained from QFT-IT supernatants was assessed by ROC
curve analysis, AUC was $0.70 for all the markers showing
significant differences between the TB cases and non-cases
including unstimulated MCP-1, MIP-1b, VEGF, IL-10, IL-1b,
CRP, MMP-9, SAA, CRP and SAP (range 0.72–0.84). When the
data was analysed by GDA, eight of the 20 most accurate 4-
analyte prediction models accurately classified 100% of the TB
cases and up to 89% of the non-TB cases after leave-one-out cross
validation (table 7). The most frequently occurring analytes in the
top 20 models included the antigen-specific levels of IL-12p70, IL-
12p40 and unstimulated IL-15 amongst others (figure 2).
Figure 2. Most frequent analytes in the most accurate GDA models. The columns represent the number of times the analyte was included
into the top-20 general discriminant analysis (GDA) models. NC: unstimulated control, Ag: antigen-stimulated marker levels, EC: ESAT-6/CFP-10.
QFT =QFT-IT, 1-day =our overnight (in-house) whole blood assay, 7-day = 7-day diluted whole blood culture assay.
doi:10.1371/journal.pone.0102584.g002
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Correlation between host marker levels detected in the
overnight, 7-day and QFT-IT whole blood culture assays
The marker levels obtained after stimulation with each antigen
(Rv2029c, Rv2032, Rv2389c and ESAT-6/CFP-10) or the
unstimulated control were compared between the assays (QFT-
IT, the in-house overnight WBA and the in-house 7-day WBA).
Comparison between the assay types was only possible for ESAT-
6/CFP-10-specific and the unstimulated control responses as these
were the only common conditions between all the assay types.
Because of the relatively large number of markers evaluated in this
study, only analytes that showed significant differences between
the TB cases and non-cases in at least one of the assay types were
included in the analysis.
Of the 26 analytes evaluated, 12 (fractalkine, IFN-a2, MCP-1,
MIP-1b, VEGF, IL-1b, IL-10, MMP-2, MMP-9, CRP, SAA, and
SAP) showed significant differences between the TB cases and non
cases in at least one of the three assays, when evaluated in
unstimulated supernatants. The levels of the markers were
compared across assays. The unstimulated levels of MCP-1,
MIP-1b and IL-1b were significantly higher in QFT-IT superna-
tants compared to the two in-house WBAs (table 8). QFT-IT levels
of the remaining unstimulated markers were similar to the levels
obtained in our in-house WBA. With the exception of fractalkine,
all unstimulated analyte levels were significantly lower (2–200 fold)
in the 7-day WBA supernatants in comparison to either the QFT-
IT or the in-house overnight WBA.
Fourteen ESAT-6/CFP-10-induced markers could discriminate
between study groups (TB vs. no TB) in at least one of the assays.
There were generally no significant differences in the levels of
markers upon stimulation with ESAT-6/CFP-10 between the
QFT-IT and our in-house overnight WBA, but generally lower
levels were obtained in the 7-day WBA supernatants (table 8).
ESAT-6/CFP10-specific IP-10 and unstimulated SAA were the
only markers that discriminated between the TB cases and non-
cases in all three WBA types (tables 2, 4 and 6). The levels of the
two analytes also correlated positively between all the three assay
types (r2 = 1, p, 0.0001 in some cases). The highest significant
correlations were observed between the QFT-IT and our in-house
overnight WBA responses (table 8, figures 5 and 6).
Discussion
In this study the potential of host markers detectable in
supernatants of M.tb infection phase-dependent antigen stimulated
whole blood culture assays was investigated in an overnight and 7-
day stimulation format for the diagnosis of TB disease. Our data
indicates that the M.tb antigens evaluated in this study elicit a
variety of host responses after short-term incubation with whole
blood. The most promising single markers obtained after
overnight culture included the Rv2032-specific levels of MMP-2,
ESAT-6/CFP10-induced sCD40L and IP-10 and unstimulated
CRP and SAA levels. Biosignatures comprising different four-
analyte combinations showed promise.
We previously showed that stimulation of whole blood with
novel M.tb infection phase dependent antigens including Rv2032,
Rv0081, Rv1737c, Rv0867c and Rv2389c resulted in the
production of multiple host markers, some of which showed
potential in the diagnosis of TB disease with high accuracy [15].
Because the 7-day WBA employed in our previous studies [15],
[18] would not be optimal as a diagnostic method for TB disease
in operational terms, we investigated if the antigens also had the
potential to elicit the production of host markers in short-term
(overnight) cultured assays. The potential clinical usefulness of any
promising diagnostic candidate markers obtained in the short-term
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assay would be evaluated prospectively in future larger validation
studies.
In the current pilot study, we enrolled 15 pulmonary TB cases
and 15 individuals that presented at the health care facility with
symptoms requiring investigation for TB, but in whom TB disease
was finally ruled out. In our investigation of candidate diagnostic
markers, we compared the levels of markers in the individuals with
confirmed TB disease to all those in whom TB disease was ruled
out (50% of whom were QFT-IT positive), regardless of QFT-IT
status. Although it is important to evaluate which markers show
differences between different M.tb infection states, for example,
comparing individuals with active TB disease vs. completely
uninfected (QFT-IT negative) individuals, or active disease vs.
latently infected (QFT-IT positive) individuals, we only focused on
the differences between TB disease and no TB disease because the
aim of this pilot study and that of the larger ongoing project, was
to identify markers that would be suitable for use in the diagnosis
of active TB, even in high burden settings, where the prevalence of
LTBI is high.
Rv2032 specific MMP-2 was the most promising antigen-
stimulated single marker obtained in the short-term WBA
experiment, with an AUC of 83%, whereas the antigen-specific
levels of EGF, MMP-9 and IP-10 amongst others, and the
unstimulated levels of CRP, SAA and SAP also showed potential
especially when the 7-day WBA and QFT-IT supernatant results
were taken into account (tables 4 and 6). However, no individual
marker consistently showed potential in all the three different
WBA types, with ESAT-6/CFP-10 specific IP-10 and unstimu-
lated SAA being the only markers showing differences between
groups in all the three WBAs. As observed in our previous studies
[15] the predictive abilities of markers improved when analytes
were used in combinations of four. The acute phase proteins
(CRP, SAA) alongside other host markers including TGF-a, EGF,
VEGF, IFN-a2 featured strongly in the top four-analyte multi-
marker models obtained in the different WBAs. The inclusion of
TGF-a, EGF, VEGF and IFN-a2 into the best discriminatory
marker models is consistent with findings from previous studies
conducted on participants from the same community [12] [15].
Consistent with these previous observations, the unstimulated
levels of IFN-a2 were higher in non-TB cases than in TB cases
[19]. The reason for the higher levels of some markers in non-TB
cases is not clear but could be due to other respiratory conditions
in the non-TB cases, given that the individuals included in this and
our previous study as controls actually presented at the health care
centre with symptoms suggestive of respiratory infections and
hence, were investigated for TB. Although we have not previously
evaluated the acute phase proteins (CRP and SAA) in previous
antigen-stimulated experiments on participants from the same
community, the inclusion of especially the unstimulated levels of
these markers into the top models is not surprising given that
serum levels of these markers have previously been shown to be
potentially useful in the diagnosis of TB disease [20]. Although the
inclusion of these markers into the most promising discriminatory
marker models implies that the markers were useful in this small
study, it should be noted that the focus of the current small study
was not on identifying a specific combination of host markers as
the ‘‘best diagnostic model’’ for TB disease, but on the
identification of markers which could be evaluated further in
larger prospective studies. Therefore, all the markers that were
most frequently included in the multi-marker models as shown in
figure 2 deserve further evaluation in future studies.
MMPs and acute phase proteins were amongst the most
important markers identified in this small study. These markers
have been shown to be involved in many diseases. Increased levels
of MMP-2 and MMP-9 have been previously associated with lung
and breast cancers [21] [22] [23]. CRP and SAA are widely used
as biomarkers for a number of conditions including pulmonary
infections [24] [25]. Although serum levels of CRP and SAA have
previously been shown to be potentially useful in the diagnosis of
TB disease [26] [20], no TB diagnostic test employing these
markers currently exists. Both the MMPs and the acute phase
proteins occurred frequently in the top four-analyte models that
most accurately discriminated between TB disease and no TB, but
none of these markers was consistently included in the top models
in all the WBA types. The results of this small study should
therefore be interpreted with caution, given the limited numbers of
study participants. That notwithstanding, if the markers identified
in this study are consistently shown to be important in the
diagnosis of TB disease either individually or in combination with
other markers in future larger studies, the detection MMPs and
acute phase proteins in clinical samples will be easier, given the
very high levels obtained in all study participants. This is in
Figure 3. Scatter-dot plots and ROC curves in overnight WBA. Representative plots showing the levels of analytes in the overnight (our in-
house) whole blood culture supernatants and ROC curves for accuracy in the diagnosis of TB disease. Error bars in the scatter-dot plots represent the
median analyte levels. Representative analytes with AUC$0.76 are shown.
doi:10.1371/journal.pone.0102584.g003
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contrast to markers such as EGF and TGF-a which also featured
in top marker models in previous studies conducted in the same
study community [19] [12], but which are expressed at low levels.
In addition to the classical TB antigens (ESAT-6 and CFP-10),
evaluated in this study as a fusion protein, three other relatively
new recombinant antigens (Rv2029c, Rv2032 and Rv2389c) were
evaluated in the overnight and 7-day WBAs. As previously
discussed [12], Rv2029c and Rv2032 are DosR regulon encoded
antigens, whereas Rv2389c is a resuscitation promoting factor
(RPF). The DosR regulon of M.tb is upregulated when M.tb is
subjected to conditions that mimic latency including hypoxia,
nutrient starvation, low nitric oxide or low pH [27] [28]. Rpfs are
growth-promoting proteins and have been shown to resuscitate
dormant bacteria, as well as enhance the growth of bacteria,
including M.tb in both liquid and solid media [29]. All the antigens
evaluated in the current study elicited host responses in both TB
and non-TB cases. This is not surprising given that 50% of our
non-TB cases were infected with M.tb, according to the QFT-IT
test [15] [12] [30] [18]. Furthermore, it is known that M.tb
infection is a spectrum [31] [32]. Higher concentrations of some
markers (for example, MMP-9 responses to Rv2029c and Rv2389c
in this study) in TB cases might therefore be expected as previously
discussed in [12].
Three of the antigens evaluated in this pilot study (Rv2032,
Rv2389c and ESAT-6/CFP-10) were previously evaluated in our
initial study evaluating the levels of multiple host markers in novel
M.tb infection phase-dependent antigens in 7-day WBA superna-
tants [15]. The promise shown by ESAT-6/CFP-10 specific EGF
in this study is consistent with the findings of the previous study.
However, the potential shown ESAT-6/CFP-10 specific TGF-a
and TNF-a were not replicated in 7-day WBA supernatants in this
study. Similarly, differences observed between the TB cases and
non-cases for Rv2389c- specific levels of TGF-a, TNF-a, VEGF,
IL-10 ,and Rv2032-specific levels of fractalkine, IL-12(p40), TGF-
a, TNF-a, VEGF and IL-10 were not replicated in the 7-day
WBA supernatants in the current study. The reason for the
discrepancies between the findings of the initial study and the
current 7-day WBA results is unknown but may relate to the small
sample size employed in the current study and differences in the
antibodies employed in the two studies. The recurrence of
common antigen-specific markers, for example, Rv2032-specific
VEGF in diagnostic models in both studies indicates the results
between the two studies might be identical, if very similar
conditions were employed. However, the current ongoing larger
validation studies in different African countries will help identify
the best candidate diagnostic markers and models.
Although the WBAs employed in the current study are different
(7-day culture vs. overnight culture, and 5-fold dilution of whole
blood in the 7-day WBA vs. undiluted blood in the overnight
assay), we compared the levels of host markers detected in
supernatants from each study participant after culture using the
different techniques. This was done in order to ascertain if any of
the potentially useful markers performs consistently in the different
WBA types. Furthermore, we assessed the correlation between our
in-house overnight WBA and the highly standardised QFT-IT
assay. The generally good correlation between the markers
detected in culture supernatants from our in-house overnight
WBA with those detected in the QFT-IT supernatants is
reassuring and suggests that both assay types are suitable for
further diagnostic marker discovery. The magnitude of responses
obtained with the two overnight assays was consistently higher
than the responses obtained in the 7-day WBAs. This could be
explained by the amount of sample that was used in the different
assay types. The two overnight assays (our in-house WBA and the
QFT-IT assay) employed 1 ml of undiluted whole blood while
blood samples were diluted five times before being evaluated in the
7-day WBA as previously recommended [12, [33]. A direct
comparison of the levels of markers detected using the three assay
types was only possible for the unstimulated and ESAT-6/CFP-
10-stimulated analyte levels (although the QFT-IT assay employs
a third antigen (TB7.7) in addition to ESAT-6/CFP-10), since
these were the only common conditions across the WBA
techniques. Higher responses were observed in the QFT-IT
antigen-stimulated and unstimulated supernatants for some
markers, in comparison to the levels obtained in our in-house
WBA supernatants. The reasons for this observation are unclear as
the same amount of undiluted blood was evaluated using the two
culture techniques. However, the QFT-IT system is a highly
Figure 4. Scatter-dot plots and ROC curves in QFT-IT assay. Representative plots showing the levels of analytes in the QFT-IT whole blood
culture supernatants and ROC curves for accuracy in the diagnosis of TB disease. Error bars in the scatter-dot plots represent the median analyte
levels. Representative analytes with AUC$0.82 are shown.
doi:10.1371/journal.pone.0102584.g004
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validated and standardized test system and uses closed tubes and
blood was drawn directly into the tubes. In comparison, blood was
drawn into sodium heparinized tubes before being aliquoted into
the wells of 24-well tissue culture plates in our in-house assay. This
observation was not investigated further as the aim of the current
study was to investigate if the relatively newer antigens elicited the
production of host markers after overnight stimulation, as opposed
to the traditional 7-day cultures, and whether the markers
possessed diagnostic potential for TB disease.
IGRAs are well established and remain the tests of choice for
the diagnosis of LTBI in many settings. However, these assays do
not discriminate between LTBI and active disease and are
therefore not recommended in high burden settings [34]. This is
mainly because of the large proportion of LTBI cases in high-
burden settings. The current study was performed in a setting with
high burden of TB. The results of the current as well as those
obtained in our previous studies [15] raise the hope that any
diagnostic tests based on these antigens and host markers, might
be highly suitable in high-burden settings. However, diagnostic
tests based on the antigens and host markers would be mostly
beneficial to TB control programs if such antigens and markers are
incorporated into rapid, point-of-care test platforms such as the
lateral flow technology. Such test platforms (based on the Up-
converting phosphor imaging technology), are currently being
investigated for many infectious diseases including TB [35] [36],
and have the ability to detect multiple host markers on a single
strip. Although a diagnostic modality based on overnight
stimulation of whole blood with M.tb specific antigens will only
yield results within 24 hours after the patient’s visit as previously
discussed [15], it might prove cheaper and more suitable in remote
Figure 5. Correlation of stimulated analyte levels across assays. Correlation between ESAT-6/CFP-10-stimulated analyte levels in
supernatants from the three whole blood cultures. Representative plots for 5 ESAT-6/CFP-10-induced host markers are shown. ns = non-significant,
* = P value,0.05, ** = P value #0.001, *** = P value,0.0001.
doi:10.1371/journal.pone.0102584.g005
Figure 6. Correlation of unstimulated analyte levels across assays. Correlation between analytes detected in unstimulated supernatants in
the three whole blood culture techniques. Representative plots for 6 host markers are shown. ns = non-significant, * = P value,0.05, ** = P value #
0.001, *** = P value,0.0001.
doi:10.1371/journal.pone.0102584.g006
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settings than the GeneXpert and conventional M.tb culture. The
latter has been the gold standard for a long time, but is not widely
available in the most highly burdened TB and resource-
constrained settings, and also dependent on the presence of
sufficient M.tb organisms in sputum, which may be hard to obtain
reliably, particularly in the context of HIV. A non-sputum based
test will also be very useful for other individuals with difficulty in
providing good quality sputum samples, such as those with extra-
pulmonary TB and children.
In addition to the small sample size, another limitation of our
study is the case-control design. However, such a design was the
most appropriate for the current study as this was a pilot study for
a larger trial that is ongoing in seven African field sites with five
European partners. Larger studies, especially studies employing
short term culture assays are needed to validate the findings of this
study, and to further down-select and validate the most accurate 3
to 5 antigen-specific or unstimulated (ex vivo) host markers.
Results of such studies will be highly beneficial to the field if HIV
infected individuals, those with extrapulmonary TB disease and
those with other lung infections, including pneumonia are
included and such studies should ideally be prospective studies
of participants with suspected TB. Any validated host markers
could then be incorporated into lateral flow devices.
Conclusion
In conclusion, the results of the current study indicate that novel
M.tb infection phase dependent antigens including Rv2029c,
Rv2032 and Rv2389c elicit the production of several host markers,
some of which have potential to be useful as TB diagnostic
candidates either singly or in combinations, in overnight whole
blood culture assays. Although none of the single antigen-induced
host markers ascertained TB disease with an AUC .0.85,
overnight culture assays yielded several four-marker models with
more than 85% sensitivity and specificity in this small study. The
potentially useful analytes identified in this pilot study require
further investigation in larger studies.
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